Join the 'Non-Small Cell Lung Cancer' group to help and get support from people like you.
Non-Small Cell Lung Cancer News
Related terms: Cancer, Lung, Non-Small Cell, Lung Cancer, Non-Small Cell, NSCLC
HIV and Smoking a Lethal Combo for the Lungs
Posted 7 days ago by Drugs.com
MONDAY, Sept. 18, 2017 – HIV patients who take their medication but also smoke are about 10 times more likely to die from lung cancer than from AIDS-related causes, a new study estimates. Lifesaving antiretroviral drugs have improved life expectancy to the point that patients now have more to fear from tobacco than HIV, said lead researcher Dr. Krishna Reddy. "Thanks to antiretroviral medicines, people with HIV are living longer," said Reddy, a pulmonologist and critical care doctor with Massachusetts General Hospital in Boston. "The bad news is that they're living long enough to get cancer." Based on the new findings, smoking cessation should be a focus of treatment, he and his colleagues said. More than 40 percent of people with HIV are smokers, a rate more than double that of the general population, Reddy said. Fatalism and depression among HIV patients often lead them to take up ... Read more
Related support groups: Smoking, HIV Infection, Smoking Cessation, Nicotine, Lung Cancer, Non-Small Cell Lung Cancer, Pre-Exposure Prophylaxis, Nicorette, Nicoderm CQ, Nicotrol Inhaler, Small Cell Lung Cancer, Commit, Habitrol, Nicotrol TD, Bronchogenic Carcinoma, Nicorelief, Nicorette DS, Nicotrol NS, ProStep
FDA Approves Mvasi (bevacizumab-awwb), a Biosimilar to Avastin
Posted 7 days ago by Drugs.com
September 14, 2017 – The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer. “Bringing new biosimilars to patients, especially for diseases where the cost of existing treatments can be high, is an important way to help spur competition that can lower healthcare costs and increase access to important therapies,” said FDA Commissioner Scott Gottlieb, M.D. “We’ll continue to work hard to ensure that biosimilar medications are brought to the market quickly, through a process that makes certain that these new medicines meet the FDA’s rigorous gold standard for safety and effectiveness.” Mvasi is approved for the treatment of adult patients with certain colorectal, lung, brain, kidney and cervical cancers ... Read more
Related support groups: Cancer, Lung Cancer, Renal Cell Carcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer, Avastin, Cervical Cancer, Glioblastoma Multiforme, Bevacizumab, Mvasi
Cancer Takes Financial Toll, Even With Insurance
Posted 10 Aug 2017 by Drugs.com
THURSDAY, Aug. 10, 2017 – Many cancer patients in the United States are shocked by their out-of-pocket costs for care – with some spending one-third of their income on treatment, a new study finds. The study looked at the financial toll of cancer treatment on people who have health insurance. The vast majority in the study had private insurance or Medicare coverage; the rest were on Medicaid, the government insurance program for poor Americans. Despite that, the study found, patients typically spent nearly $600 a month on their treatment. Overall, 16 percent said they were facing "high or overwhelming financial distress." Those patients were spending nearly one-third of their monthly income on cancer care. Dr. Yousuf Zafar, the senior researcher on the study, used the term "financial toxicity." "Oncologists talk about the toxicities of cancer treatment. But there can also be a ... Read more
Related support groups: Anxiety and Stress, Cancer, Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Skin Cancer, Small Cell Lung Cancer, Melanoma - Metastatic, Stomach Cancer, Head and Neck Cancer, Gastric Cancer, Testicular Cancer, Choriocarcinoma
Treatment Costs Can Be Another Blow to Cancer Patients
Posted 27 Jul 2017 by Drugs.com
THURSDAY, July 27, 2017 – The emotional and physical costs of cancer can be staggering. But the financial side of cancer is also a great burden, with many patients in the United States struggling to pay for treatment, new research reveals. "The current health law has greatly improved access to meaningful health coverage for cancer patients, survivors and all those with chronic diseases," Chris Hansen, president of the American Cancer Society Cancer Action Network, said in a network news release. "Yet costs remain a challenge for those facing cancer. Our country and our lawmakers should come together to find bipartisan solutions that begin to address patient costs without sacrificing the quality of coverage," he urged. Researchers surveyed financial navigators at 11 hospitals in nine states. Financial navigators – typically trained social workers or nurses – help cancer patients ... Read more
Related support groups: Cancer, Depo-Provera, Provera, Breast Cancer, Lupron, Prostate Cancer, Medroxyprogesterone, Tamoxifen, Arimidex, Lupron Depot, Femara, Gleevec, Lung Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Anastrozole, Brain Tumor, Letrozole, Tarceva, Megestrol
Insured, But Still Barred From Top-Tier Cancer Centers
Posted 20 Jul 2017 by Drugs.com
THURSDAY, July 20, 2017 – Choosing a cheaper health plan could cost you access to cream-of-the-crop cancer doctors and facilities, a new study reports. Less-expensive "narrow network" health plans are much less likely to cover treatment by doctors at centers affiliated with the U.S. National Cancer Institute, said study lead author Laura Yasaitis. "We found that the narrower networks were more likely to systematically exclude NCI-affiliated physicians," said Yasaitis, a postdoctoral researcher with the University of Pennsylvania School of Medicine. "The oncologists they included in their networks were about half as likely to be NCI-affiliated as those they excluded." NCI-Designated Cancer Centers are the nation's top-flight facilities for cancer care, and studies have shown that patients treated at these centers tend to have better outcomes, Yasaitis said. Access to these centers is ... Read more
Related support groups: Cancer, Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Brain Tumor, Cervical Cancer, Breast Cancer, Prevention, Head and Neck Cancer, Gastric Cancer
More Patients OK'd for Cancer Trials Under Obamacare: Study
Posted 20 Jul 2017 by Drugs.com
THURSDAY, July 20, 2017 – The Affordable Care Act has enabled more privately insured patients to enroll in clinical trials for new cancer treatments, a new study contends. Speedy approvals are important for patients who want to participate in clinical trials, said study author Dr. David Hong. He's deputy chair of investigational cancer therapeutics at the University of Texas MD Anderson Cancer Center. Since 2000, Medicare, the publicly funded insurance program for seniors, has covered routine costs of clinical trial participation. But coverage for patients with private insurance differed by insurer and state, the researchers noted. Under the ACA, or Obamacare, however, private insurers had to cover "standard of care" costs of clinical trial participation as of 2014. For this study, the researchers analyzed more than 2,400 patient referrals to the Clinical Center for Targeted Therapy at ... Read more
Related support groups: Cancer, Breast Cancer, Prostate Cancer, Gleevec, Lung Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Votrient, Tarceva, Avastin, Tasigna, Pancreatic Cancer, Sutent, Sprycel, Afinitor, Nexavar, Stomach Cancer, Carboplatin, Cisplatin, Cyclophosphamide
Many Terminal Cancer Patients Remain in Denial
Posted 20 Jul 2017 by Drugs.com
WEDNESDAY, July 19, 2017 – Nearly 10 percent of patients with terminal cancer don't want to know they're dying, which can make their final days more difficult, a new study finds. Unwillingness to face poor prospects can lead to unnecessary treatments and keep patients from making end-of-life plans, the researchers reported recently in The Oncologist. "Health care professionals should appropriately assess patients' readiness for prognostic information," said study leader Siew-Tzuh Tang, a professor at Chang Gung University School of Nursing in Taiwan. Doctors should respect patients' reluctance to confront their poor prognosis if they are not ready to know, "but sensitively coach them to cultivate their accurate prognostic awareness," Tang said in a journal news release. The study involved nearly 250 terminal cancer patients in Taiwan. They were questioned several times over their last ... Read more
Related support groups: Anxiety, Generalized Anxiety Disorder, Anxiety and Stress, Cancer, Post Traumatic Stress Disorder, Social Anxiety Disorder, Breast Cancer, Prostate Cancer, Lung Cancer, Renal Cell Carcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Metastatic, Brain Tumor, Skin Cancer, Ovarian Cancer, Pancreatic Cancer, Cervical Cancer, Stomach Cancer, Breast Cancer, Prevention
For Holocaust Survivors, Raised Risk of Cancer
Posted 10 Jul 2017 by Drugs.com
MONDAY, July 10, 2017 – Holocaust survivors face an increased risk for cancer, a new study finds. The study included more than 152,600 survivors of the World War II genocide who were followed for more than 45 years. The researchers compared whether these survivors received compensation for their suffering and whether they were born in Nazi-occupied countries. Cancer was diagnosed in 22 percent of compensated survivors and 16 percent of the others, the findings showed. Compensated survivors were 6 percent more likely to develop any type of cancer; 12 percent more likely to have colorectal cancer; and 37 percent more likely to have lung cancer. In addition, the investigators found that people born in occupied countries had an 8 percent higher cancer risk. Their risk of colorectal cancer was also 8 percent higher, and their risk of lung cancer was 12 percent higher. Female holocaust ... Read more
Related support groups: Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Breast Cancer, Prevention, Breast Cancer - Palliative, Diagnosis and Investigation
Publicly Funded Cancer Trials Gained Americans 3 Million More Years
Posted 6 Jun 2017 by Drugs.com
TUESDAY, June 6, 2017 – Public-funded trials have significantly extended the lives of people diagnosed with cancer, according to new research. SWOG, the clinical trials network funded by the U.S. National Cancer Institute (NCI), has involved more than 200,000 patient volunteers. These trials have led to approval of 14 new cancer drugs and more than 100 changes to cancer care standards. All told, the clinical trials studied extended life by 3.34 million years, the study found. SWOG estimates the dollar return on investment from federal funding at $125 for each year of life gained. "A lot of people with cancer have lived longer because of the therapies tested in our publicly funded trials," study leader Joseph Unger said in a SWOG news release. He is an assistant member of the Fred Hutchinson Cancer Research Center's Cancer Prevention Program in Seattle. "At the same time, the cost of ... Read more
Related support groups: Cancer, Depo-Provera, Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Prostate Cancer, Medroxyprogesterone, Tamoxifen, Arimidex, Tretinoin, Fluorouracil, Lupron Depot, Femara, Gleevec, Rituxan, Lung Cancer, Isotretinoin, Colorectal Cancer
Gene-Targeted Drugs Fight Advanced Lung Cancers
Posted 5 Jun 2017 by Drugs.com
MONDAY, June 5, 2017 – Two drugs that target genetic flaws are giving people with specific types of advanced lung cancer a chance to live longer and better, a pair of new clinical trials finds. A newly approved drug called alectinib (Alecensa) works twice as long as the current standard medication in halting cancer growth in patients with ALK-positive non-small cell lung cancer, results from a new global clinical trial show. ALK is a gene that produces a protein that helps cancer cells grow and spread, according to the American Cancer Society (ACS). In another study, an experimental drug called dacomitinib delayed cancer growth by about half in non-small cell lung cancer patients who had a mutation of the epidermal growth factor receptor (EGFR) that caused cancer cells to grow faster, a second trial reported. Non-small cell lung cancers comprise most lung cancer cases. EGFR is a ... Read more
Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Xalkori, Iressa, Gefitinib, Crizotinib, Alectinib, Alecensa
Suicide Risk Quadruples After Lung Cancer Diagnosis
Posted 23 May 2017 by Drugs.com
TUESDAY, May 23, 2017 – People with lung cancer have a strikingly higher-than-normal risk of suicide, a new study finds. While a cancer diagnosis on its own significantly raises the risk of suicide, the study found that a lung cancer diagnosis raised the odds of suicide by over four times compared to people in the general population. "A cancer diagnosis is an overwhelming diagnosis for patients psychologically and emotionally," explained study senior author Dr. Jeffrey Port. "It is a very tough diagnosis for patients to manage, and there is a higher suicide rate," he added. Port is a professor of cardiothoracic surgery at Weill Cornell Medical Center in New York City. The study included data from over 3 million patients during a 40-year period. Cancer diagnoses were linked to over 6,600 suicides. Although the study wasn't designed to prove a direct cause-and-effect relationship, the ... Read more
Related support groups: Depression, Anxiety, Anxiety and Stress, Major Depressive Disorder, Smoking, Smoking Cessation, Lung Cancer, Non-Small Cell Lung Cancer, Dysthymia
Takeda Announces FDA Accelerated Approval of Alunbrig (brigatinib)
Posted 29 Apr 2017 by Drugs.com
Cambridge, Mass. and Osaka, Japan – April 28, 2017 – Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that Alunbrig (brigatinib) has received Accelerated Approval from the U.S. Food and Drug Administration (FDA) for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under Accelerated Approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Alunbrig, which previously received Breakthrough Therapy Designation from the FDA, is a once-daily oral therapy that may be taken with or without food. “In recent years, small molecule ALK inhibitors have revolutionized the treatment options fo ... Read more
Related support groups: Non-Small Cell Lung Cancer, Brigatinib, Alunbrig
Study Says Blood-Chromosome Test Predicts Lung Cancer's Return
Posted 26 Apr 2017 by Drugs.com
WEDNESDAY, April 26, 2017 – Unstable chromosomes within lung cancer tumors increase the risk that the cancer will return after surgery, researchers report. The investigators said they used this new information to forecast the return of lung cancer long before standard tests could spot it. The findings were published April 26 in the New England Journal of Medicine and Nature. The Cancer Research UK-funded TRACERx study included 100 patients with non-small cell lung cancer. The study participants were followed from diagnosis, through surgery, to either cure or disease relapse. Patients with a high proportion of unstable chromosomes in their tumors had more than quadruple the risk of their cancer returning, or of dying from their disease, within two years, the findings showed. The study offers "new insights into how tumors evolve and evade treatment, a leading cause of cancer death," lead ... Read more
Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Diagnosis and Investigation
Drug Offers Some Hope for a Deadly Lung Cancer
Posted 4 Apr 2017 by Drugs.com
TUESDAY, April 4, 2017 – The cancer drug Opdivo (nivolumab) may offer hope of a longer life for some patients with advanced lung cancer, a new small study finds. Currently, only about 5 percent of patients with advanced non-small-cell lung cancer survive five years or more. But that rate rose to about 16 percent among a group taking Opdivo, researchers reported Monday. "For the first time we are reporting long-term survival for patients with advanced lung cancer," said lead researcher Dr. Julie Brahmer. Brahmer is an associate professor of oncology at the Johns Hopkins University Institute for Cancer Immunotherapy in Baltimore. Opdivo is an immunotherapy drug, which means it enlists the patient's own immune system to fight diseases such as cancer. "Immune therapy may play a role in almost any cancer. We are working to increase the response in lung cancer patients," Brahmer said. Opdivo ... Read more
Related support groups: Non-Small Cell Lung Cancer, Opdivo, Nivolumab
Tagrisso (osimertinib) Receives FDA Full Approval
Posted 3 Apr 2017 by Drugs.com
31 March 2017 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted full approval for Tagrisso (osimertinib) 80mg once-daily tablets, for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after an EGFR tyrosine kinase inhibitor (TKI) therapy. Tagrisso is the first and only approved medicine in the US indicated for NSCLC patients who have tested positive for the EGFR T790M mutation, and efficacy data suggest it may be a new standard of care for these patients. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “By following the science, we aim to turn lung cancer into a chronic, manageable disease for patients and this m ... Read more
Related support groups: Non-Small Cell Lung Cancer, Osimertinib, Tagrisso
Ask a Question
Further Information
Related Condition Support Groups
Related Drug Support Groups
methotrexate, Tarceva, Avastin, Taxol, Opdivo, Keytruda, Taxotere, Xalkori, cisplatin, view more... cyclophosphamide, capecitabine, paclitaxel, Iressa, Gemzar, nivolumab, gemcitabine, Tecentriq, erlotinib, Alimta, Cyramza, pembrolizumab, docetaxel, Abraxane, crizotinib, gefitinib, bevacizumab, Platinol, Navelbine, Gilotrif, amifostine, ramucirumab, vinorelbine, afatinib, Trexall, cetuximab, alectinib, Alecensa, osimertinib, Tagrisso, Methotrexate LPF Sodium, pemetrexed, Alunbrig, Portrazza, paclitaxel protein-bound, Zykadia, porfimer, Ethyol, Docefrez, brigatinib, ceritinib, Platinol-AQ, Folex PFS, necitumumab, Photofrin, atezolizumab, Onxol, Mvasi
